Biological biopharmaceuticals are crucial in medical treatment and diagno
stics, including vaccines, antibodies, and protein drugs. The global protein
therapeutics market is projected to reach $390 billion by 2026, growing at
8.3% annually. Expired patents will drive biosimilar research and substanti
al production equipment investment.
To overcome challenges in biopharmaceutical production, our team devel

oped a compact continuous protein purification system using 3D microflu
idic technology. It enables continuous purification, enhancing volumetric
productivity while maintaining protein activity. The system integrates proc
esses, reduces control components and pipelines by 90%, and offers dispo
sable components for contamination prevention. Its miniaturized design,
similar to a desktop computer, includes automated systems, real-time det
ection, and a cooling system for on-site deployment.
Key features of our innovation include:
1. Process integration. Reducing control components to 2 sets and shorte
ning purification time to one-fourth of the original.
2. Integration of control components and pipelines into a single unit. Red
ucing pipeline usage by 90%.
3. Disposable control components. Eliminating cross-contamination and r
educing cleaning time by 2-3 hours.
4. Equipment miniaturization. Reducing ineffective volume by 90%.
5. Intelligent operation. Allowing optimized scheduling based on purificat
ion conditions.
6. Fully enclosed system. Preventing contamination during purification.
Our continuous protein purification technology provides efficient, reliabl
e, and controllable protein purification. It reduces solvent and resin usage
by 75% and saves cleaning time, generating economic benefits. This innov
ation meets the increasing demand for protein therapeutics, advancing th
e biopharmaceutical industry.